PTPRC and neoplasm: By contrast, the Oxali + anti–PD-L1 combo decreased the fractions of each tumor occupied by CD45− “cancer” cells, an effect that was most pronounced in WT tumors relative to p300 or IFNγR2 ablated tumors (Fig. 7O).